NL300798I2 - - Google Patents

Info

Publication number
NL300798I2
NL300798I2 NL300798C NL300798C NL300798I2 NL 300798 I2 NL300798 I2 NL 300798I2 NL 300798 C NL300798 C NL 300798C NL 300798 C NL300798 C NL 300798C NL 300798 I2 NL300798 I2 NL 300798I2
Authority
NL
Netherlands
Prior art keywords
amino acid
absent
acid sequence
salp
alkaline phosphatase
Prior art date
Application number
NL300798C
Other languages
English (en)
Other versions
NL300798I1 (nl
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of NL300798I1 publication Critical patent/NL300798I1/nl
Publication of NL300798I2 publication Critical patent/NL300798I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
NL300798C 2007-05-11 2016-02-26 NL300798I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (2)

Publication Number Publication Date
NL300798I1 NL300798I1 (nl) 2016-03-16
NL300798I2 true NL300798I2 (nl) 2016-03-16

Family

ID=40001639

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300798C NL300798I2 (nl) 2007-05-11 2016-02-26

Country Status (25)

Country Link
US (1) US20100297119A1 (nl)
EP (3) EP2158319B1 (nl)
JP (1) JP5732603B2 (nl)
AT (1) ATE536413T1 (nl)
AU (1) AU2008250945B2 (nl)
BR (2) BR122019000505B1 (nl)
CA (1) CA2687001C (nl)
CY (1) CY2016005I2 (nl)
DE (1) DE202008018131U1 (nl)
DK (3) DK2158319T3 (nl)
ES (3) ES2380546T3 (nl)
HK (3) HK1141047A1 (nl)
HR (1) HRP20140416T1 (nl)
HU (2) HUE031655T2 (nl)
IL (1) IL202057A0 (nl)
LT (1) LTC2368999I2 (nl)
LU (1) LU92976I2 (nl)
ME (1) ME01828B (nl)
NL (1) NL300798I2 (nl)
NO (1) NO2016002I2 (nl)
PL (3) PL2662448T3 (nl)
PT (3) PT2662448T (nl)
RS (1) RS53302B (nl)
SI (2) SI2662448T1 (nl)
WO (1) WO2008138131A1 (nl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3404102B1 (en) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
US8680237B2 (en) 2007-06-01 2014-03-25 Gliknik Inc. Immunoglobulin constant region FC receptor binding agents
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
SG185079A1 (en) * 2010-04-30 2012-12-28 Alexion Pharma Internat Sarl Methods, compositions, and kits for the treatment of matrix mineralization disorders
MX347343B (es) 2010-07-28 2017-04-21 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
KR20140084201A (ko) * 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
DK3097189T3 (en) * 2014-01-24 2018-09-03 Am Pharma Bv CHEMICAL ALKALISK PHOSPHATASE-LIKE PROTEINS
US10822596B2 (en) * 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
AU2015357551B2 (en) * 2014-12-05 2021-02-25 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP3337894A1 (en) * 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) * 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
US11065306B2 (en) * 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
MX2018011833A (es) * 2016-04-01 2019-02-13 Alexion Pharma Inc Tratamiento para la debilidad muscular con fosfatasas alcalinas.
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
ES2887573T3 (es) 2016-06-27 2021-12-23 Alexion Pharma Inc Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
MX2019006189A (es) * 2016-11-30 2019-11-18 Purdue Research Foundation Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.
TW201835098A (zh) 2016-12-09 2018-10-01 美商吉林尼克公司 製備最佳化之多聚化斯塔都聚體(stradomer) gl-2045
JP7142021B2 (ja) * 2017-03-09 2022-09-26 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質製造プロセス
CA3057502A1 (en) * 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
EP3768302A4 (en) 2018-03-20 2021-12-15 Synthetic Biologics, Inc. INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
JP2021519590A (ja) * 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
CN110499285A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Alpl基因在制备预防和/或治疗低碱性磷酸酶症的产品中的应用
BR112022011286A2 (pt) * 2019-12-09 2022-09-06 Alexion Pharma Inc Polipeptídeos da fosfatase alcalina e métodos de uso dos mesmos
AU2021338361A1 (en) * 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
US20220265784A1 (en) * 2021-02-12 2022-08-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP1232276B8 (en) 1999-11-16 2007-06-27 Genzyme Corporation Vectors and transgenes with regulatory elements for gene delivery to the liver
WO2002092134A1 (en) 2001-05-14 2002-11-21 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
EP3404102B1 (en) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
WO2006039480A2 (en) * 2004-09-29 2006-04-13 The Burnham Institute For Medical Research Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
JP2008521575A (ja) 2004-12-01 2008-06-26 ジェンザイム・コーポレイション 肝臓を標的とした遺伝物質の送達方法

Also Published As

Publication number Publication date
WO2008138131A1 (en) 2008-11-20
AU2008250945B2 (en) 2013-12-12
DK2158319T3 (da) 2012-03-19
EP2158319B1 (en) 2011-12-07
EP2368999A1 (en) 2011-09-28
HUS1600005I1 (hu) 2016-02-29
PL2368999T3 (pl) 2014-08-29
PT2368999E (pt) 2014-05-26
WO2008138131A9 (en) 2009-08-06
PL2158319T3 (pl) 2012-05-31
EP2662448B1 (en) 2016-12-21
NO2016002I2 (no) 2016-02-02
CY2016005I1 (el) 2016-08-31
ATE536413T1 (de) 2011-12-15
HK1141047A1 (en) 2010-10-29
EP2158319A4 (en) 2010-07-21
SI2662448T1 (sl) 2017-05-31
BRPI0811198B1 (pt) 2021-03-09
BRPI0811198A8 (pt) 2018-07-31
DK2662448T3 (en) 2017-03-20
NL300798I1 (nl) 2016-03-16
AU2008250945A2 (en) 2009-12-24
CY2016005I2 (el) 2016-08-31
ME01828B (me) 2014-12-20
JP5732603B2 (ja) 2015-06-10
ES2619332T3 (es) 2017-06-26
PT2158319E (pt) 2012-03-06
PT2662448T (pt) 2017-03-29
RS53302B (en) 2014-08-29
CA2687001C (en) 2019-02-12
US20100297119A1 (en) 2010-11-25
NO2016002I1 (nl) 2016-02-02
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
HK1191372A1 (zh) 2014-07-25
BR122019000505B1 (pt) 2022-01-18
LTC2368999I2 (lt) 2017-09-25
EP2158319A1 (en) 2010-03-03
BR122019000505A2 (pt) 2021-12-14
DE202008018131U1 (de) 2011-12-30
WO2008138131A4 (en) 2008-12-31
BRPI0811198A2 (pt) 2014-10-21
ES2471915T3 (es) 2014-06-27
PL2158319T4 (pl) 2016-04-29
AU2008250945A1 (en) 2008-11-20
BRPI0811198B8 (pt) 2021-05-25
JP2010526543A (ja) 2010-08-05
HK1162589A1 (en) 2012-08-31
ES2380546T3 (es) 2012-05-16
LU92976I2 (en) 2016-04-11
DK2368999T3 (da) 2014-05-26
HRP20140416T1 (hr) 2014-06-20
CA2687001A1 (en) 2008-11-20
LTPA2016004I1 (lt) 2016-02-25
PL2662448T3 (pl) 2017-07-31
EP2368999B1 (en) 2014-03-12
IL202057A0 (en) 2011-08-01
SI2368999T1 (sl) 2014-07-31

Similar Documents

Publication Publication Date Title
NL300798I2 (nl)
BRPI0414593A (pt) derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
BRPI0414598A (pt) indóis substituìdos
HRP20090245T1 (en) Pyy agonists and uses thereof
RS52843B (en) THE NEW IS THE HYDROGEN SULPHATE
MX347545B (es) Polipeptidos con actividad xilanasa.
TW200630367A (en) Substituted adenines and the uses thereof
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
HUP0101317A2 (hu) Módosított VIII-as faktor
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
BR0110999A (pt) Misturas de adesivos aquosos
DK2084198T3 (da) Beklædningssammensætning
TW200613604A (en) Preparation of fabrics having lotus leaf effect and fabrics having lotus leaf effect
MY150639A (en) T cell adhesion molecule and antibody thereto
FR2902101B1 (fr) Peptides a activite anti-proliferative
CY1115263T1 (el) Αλκαλικη φωσφαταση στοχευμενη στα οστα, κιτ και μεθοδοι χρησης αυτων